The Honorable James C. Greenwood, former President and CEO, Biotechnology Innovation Organization (BIO), based in Washington, DC

Just as we enter the golden age of gene therapy, cell therapy, immunotherapy, CRISPR and advances in vaccine technology, elected officials in the White House, Congress, governors’ mansions and state legislatures are poised to kill medical innovation. Will cynical and/or ignorant politicians pass laws that will drive investment away from the life sciences and undermine the promise of treating and curing untold numbers of diseases? Jim Greenwood, the former President and CEO of the Biotechnology Innovation Organization (BIO), United States Representative and state legislator shared his predictions about how the November 2020 elections would shape the future of drug development.

Meet Jim by logging in to Cavendish IQ.

John VeLure, President and CEO, i-Lumen Scientific, Inc., based in Bloomington, Minn.

Imagine losing the ability to read, drive or walk without assistance. Age-related macular degeneration (or AMD) is a debilitating visual disease that destroys quality of life. It affects the central field of vision and this progressive disease is the leading cause of blindness in those over 65, with more than 1 in 4 people being afflicted with AMD. Worldwide, it affects 110 Million people – including 26.0 Million in the US and Europe.

Now, imagine having a solution that can restore lost vision. i-Lumen's non-surgical, office-based therapeutic uses surface micro-current stimulation applied to the eye to restore and mitigate this degenerative visual disease. The 5 day treatment regimen has demonstrated effectiveness in more than 60% of patients treated. This innovative technology will enable ophthalmic practices to finally treat a patient population that they could only previously monitor vision degradation overtime. Learn about i-Lumen’s breakthrough ophthalmic technology that will not only help reduce overall society costs but addresses a significant humanitarian issue – enabling our senior population to maintain their independence and ‘age-in-place’.

John Velure, President & CEO, has more than 20 years experience in leading medical device companies leveraging surface neural stimulation to treat a variety of chronic health conditions. Previously, he was Founder and President of Neurotech, a surface neural stimulation company, specializing in orthopedic therapies, which he sold to Theragen in 2015 for a significant multiple. He also served as SVP of business development at Medibio, a publicly traded mental health diagnostic company. Prior to this, he was Senior Director at Compex Technologies US, a world leader in surface neural stimulation for pain management and rehabilitation, and led the growth of the US medical business, which led to the sale of the Company to Encore Medical/DJO. Mr. Velure was also Director of Sales and Marketing for American Medtech, a urology company that utilized surface compression and stimulation for the treatment of ED and led the sale of the Company to Pos-T-Vac, a leader in ED devices.

Meet John and i-Lumen by logging in to Cavendish IQ.

Michael Choukas, CEO, Autem Medical, Inc., based in Hanover, NH

The Autem gEM™ System leverages our novel electromagnetic technology to offer safe, non-invasive, non-toxic and accessible treatment for advanced stage cancer patients with no or limited treatment options. Autem’s proprietary amplitude-modulated electromagnetic frequency (AM-EMF) technology, algorithms and AI identify dynamic patient-specific frequencies for patient prognosis, treatment and stratification for care and risk management. Patients live longer, with a higher activity level and quality of life, often with reduced exposure to toxic late stage treatments and consumption of healthcare services.

Meet Michael and Autem Medical by logging in to Cavendish IQ.